HuGE Literature Finder
Records
1
-
10
| Genetic Polymorphisms Affecting Tacrolimus Metabolism and the Relationship to Post-Transplant Outcomes in Kidney Transplant Recipients. Pharmacogenomics and personalized medicine 2021 14 1463-1474. Cheng Fang, Li Qiang, Wang Jinglin, Hu Min, Zeng Fang, Wang Zhendi, Zhang |
| Polymorphisms of Drug-Metabolizing Enzymes and Transporters Contribute to the Individual Variations of Erlotinib Steady State Trough Concentration, Treatment Outcomes, and Adverse Reactions in Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer Patients. Frontiers in pharmacology 2020 11 664. Liao Dehua, Liu Zhigang, Zhang Yongchang, Liu Ni, Yao Dunwu, Cao Lizhi, Chen Yun, Fu Yilan, Yang Nong, Xiang Daxio |
| Pharmacokinetics and safety of erlotinib and its metabolite OSI-420 in infants and children with primary brain tumors. Cancer chemotherapy and pharmacology 2019 Aug . Reddick Samuel J, Campagne Olivia, Huang Jie, Onar-Thomas Arzu, Broniscer Alberto, Gajjar Amar, Stewart Clinton |
| Association of pharmacokinetics and pharmacogenomics with safety and efficacy of gefitinib in patients with EGFR mutation positive advanced non-small cell lung cancer. Lung cancer (Amsterdam, Netherlands) 2016 Mar 93 69-76. Hirose Takashi, Fujita Ken-Ichi, Kusumoto Sojiro, Oki Yasunari, Murata Yasunori, Sugiyama Tomohide, Ishida Hiroo, Shirai Takao, Nakashima Masanao, Yamaoka Toshimitsu, Okuda Kentaro, Ohmori Tohru, Sasaki Yasutsu |
| Relationship Among Gefitinib Exposure, Polymorphisms of Its Metabolizing Enzymes and Transporters, and Side Effects in Japanese Patients With Non-Small-Cell Lung Cancer. Clinical lung cancer 2015 Jul 16 (4): 274-81. Kobayashi Hiroyuki, Sato Kazuhiro, Niioka Takenori, Miura Hajime, Ito Hiroshi, Miura Masato |
| Population pharmacokinetics/pharmacodynamics of erlotinib and pharmacogenomic analysis of plasma and cerebrospinal fluid drug concentrations in Japanese patients with non-small cell lung cancer. Clinical pharmacokinetics 2013 Jul 52 (7): 593-609. Fukudo Masahide, Ikemi Yasuaki, Togashi Yosuke, Masago Katsuhiro, Kim Young Hak, Mio Tadashi, Terada Tomohiro, Teramukai Satoshi, Mishima Michiaki, Inui Ken-Ichi, Katsura Toshi |
| Early sorafenib-induced toxicity is associated with drug exposure and UGTIA9 genetic polymorphism in patients with solid tumors: a preliminary study. PloS one 2012 7 (8): e42875. Boudou-Rouquette Pascaline, Narjoz Céline, Golmard Jean Louis, Thomas-Schoemann Audrey, Mir Olivier, Taieb Fabrice, Durand Jean-Philippe, Coriat Romain, Dauphin Alain, Vidal Michel, Tod Michel, Loriot Marie-Anne, Goldwasser François, Blanchet Beno |
| Integrated pharmacogenetic prediction of irinotecan pharmacokinetics and toxicity in patients with advanced non-small cell lung cancer. Lung cancer (Amsterdam, Netherlands) 2009 Jan 63 (1): 115-20. Han Ji-Youn, Lim Hyeong-Seok, Park Yong Hoon, Lee Sung Young, Lee Jin S |
| [Factors responsible for inter-individual variations in dosage/concentration of tacrolimus in renal transplant recipients]. Nan fang yi ke da xue xue bao = Journal of Southern Medical University 2008 Dec 28 (12): 2161-4. Fu Shao-jie, Wang Yan-bin, Yu Li-xin, Li Qiang, Wang Yi-bin, Xiao Lu- |
| Pharmacogenomic and pharmacokinetic determinants of erlotinib toxicity. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008 Mar 26 (7): 1119-27. Rudin Charles M, Liu Wanqing, Desai Apurva, Karrison Theodore, Jiang Xuemin, Janisch Linda, Das Soma, Ramirez Jacqueline, Poonkuzhali Balasubramanian, Schuetz Erin, Fackenthal Donna Lee, Chen Peixian, Armstrong Deborah K, Brahmer Julie R, Fleming Gini F, Vokes Everett E, Carducci Michael A, Ratain Mark |
- Page last reviewed:Oct 1, 2021
- Page last updated:Jan 12, 2022
- Content source: